Clinical trial NCT03345927: Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction
Official title: Investigation of Association Between Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction in Cardiovascular Disease Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Keywords: S-adenosylhomocysteine
Endothelial function
Lead sponsor: Shenzhen Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
Collaborators: name: Peking University Shenzhen Hospital
First posted: 2017-11-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with high cardiovascular risk, or diagnosed as coronary artery disease.

Brief summary: To investigate the relationship betweeen plasma S-adenosylhomocysteine (SAH) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,who will be measaured the flow-mediated dilation by B-ultrasound, and then measaured the plasma levels of methionine metabolites, such as SAH, SAM, and analyze the association.

Detailed description: To investigate the relationship betweeen plasma S-adenosylhomocysteine (SAH) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,who will be measaured the flow-mediated dilation by B-ultrasound, and then use HPLC-MS/MS to measaure the plasma levels of methionine metabolites, such as SAH, SAM, and use methylated specifical PCR to detect the promoter DNA methylation of p66shc, and use ELISA kits to measure the plasma ROS levels of CVD patients, such as MDA, 8-iso-prostaglandin F2a, and finally analyze the association between SAH, ROS levels, promoter DNA methylation of p66shc, and flow-mediated dilation.

Eligibility criteria: Inclusion Criteria:

* patients who have stable clinical conditions, except for acute coronary syndromes, and the availability of measurement of flow-mediated dilation, or have more than three cardiovascular traditional risk factors, such as smoking, alcohol use, obesity, hypertesion, diabetes, family history, and so on.

Exclusion Criteria:

* critical illness or hemodynamic instability other than acute coronary syndromes, surgery, or trauma within the previous month, known cancer, hepatic failure or hepatitis, or the use of drugs, such as anticancer agents, which would affect plasma tHcy concen-trations.

Primary outcomes:
measure: Endothelial function
timeFrame: one month after enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Chun Wang
state: Guangdong
Study officials:
affiliation: Shenzhen CDC
name: Yuebin Ke, Dr.
role: STUDY_DIRECTOR
References:
citation: Xiao Y, Xia J, Cheng J, Huang H, Zhou Y, Yang X, Su X, Ke Y, Ling W. Inhibition of S-Adenosylhomocysteine Hydrolase Induces Endothelial Dysfunction via Epigenetic Regulation of p66shc-Mediated Oxidative Stress Pathway. Circulation. 2019 May 7;139(19):2260-2277. doi: 10.1161/CIRCULATIONAHA.118.036336.